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Abstract
Background: Generalised anxiety disorder (GAD) is the most common anxiety disorder in older people. First-line
management includes pharmacological and psychological therapies, but many do not find these effective or acceptable. Little
is known about how to manage treatment-resistant generalised anxiety disorder (TR-GAD) in older people.
Objectives: To examine the acceptability, feasibility and preliminary estimates of the effectiveness of acceptance and
commitment therapy (ACT) for older people with TR-GAD.
Participants: People aged ≥65 years with TR-GAD (defined as not responding to GAD treatment, tolerate it or refused
treatment) recruited from primary and secondary care services and the community.
Intervention: Participants received up to 16 one-to-one sessions of ACT, developed specifically for older people with TR-
GAD, in addition to usual care.
Measurements: Co-primary outcomes were feasibility (defined as recruitment of ≥32 participants and retention of ≥60%
at follow-up) and acceptability (defined as participants attending ≥10 sessions and scoring ≥21/30 on the satisfaction with
therapy subscale). Secondary outcomes included measures of anxiety, worry, depression and psychological flexibility (assessed
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Results: Thirty-seven participants were recruited, 30 (81%) were retained and 26 (70%) attended ≥10 sessions. A total of
18/30 (60%) participants scored≥21/30 on the satisfaction with therapy subscale.There was preliminary evidence suggesting
that ACT may improve anxiety, depression and psychological flexibility.
Conclusions: There was evidence of good feasibility and acceptability, although satisfaction with therapy scores suggested
that further refinement of the intervention may be necessary. Results indicate that a larger-scale randomised controlled trial
of ACT for TR-GAD is feasible and warranted.
Keywords:older people, generalised anxiety disorder, treatment-resistant, acceptance and commitment therapy, feasibility
Key Points
• There is a lack of evidence to guide the management of treatment-resistant GAD (TR-GAD) in older people.
• A psychological intervention based on acceptance and commitment therapy (ACT) was developed for older people with
TR-GAD.
• ACTwas feasible and acceptable to older people with TR-GAD, but further refinement of the interventionmay be necessary.
• There was preliminary evidence of improvements in anxiety, depression and psychological flexibility, which is promising.
• Further research is needed to establish the clinical and cost-effectiveness of ACT for older people with TR-GAD.
Introduction
Generalised anxiety disorder (GAD) is the most common
anxiety disorder in older people, with an estimated preva-
lence of 1.2–11.2% [1]. It is characterised by excessive anx-
iety and worry, including feelings of fear, dread and uneasi-
ness, experienced as being difficult to control, on more days
than not for at least 6 months [2]. Other symptoms include
restlessness or feeling on edge, fatigue, irritability, muscle
tension and difficulties with concentrating and sleeping. It
may persist for decades, with a mean symptom duration
of 20–30 years [3]. It is associated with numerous negative
outcomes in older people, including poorer health-related
quality of life, increased disability and greater healthcare
utilisation in comparison to non-anxious older people [4].
Comorbidity with other mood and personality disorders is
common and is associated with poorer outcomes [5].
First-line management of GAD includes pharmacother-
apy (e.g. selective serotonin reuptake inhibitors) and psy-
chotherapy (e.g. cognitive behavioural therapy (CBT) and
applied relaxation). However, many older people with GAD
find these treatments ineffective, lacking acceptability (e.g.
due to side effects) or unable to produce a sustained benefit
[6], leaving clinicians uncertain as to how best to manage
this condition. At present, there is a lack of evidence to guide
the management of GAD that has not responded adequately
to first-line pharmacological and psychological interventions
(i.e. treatment-resistant GAD [TR-GAD] [7]). For example,
a previous systematic review was unable to identify any ran-
domised controlled trial (RCT) or prospective comparative
observational study of pharmacotherapy or psychotherapy
for treatment-resistant anxiety in older people [8].
Meta-analytic evidence of lower efficacy of CBT for GAD
in older people compared to working-age adults [9] suggests
that an alternative form of psychological interventionmay be
required for managing TR-GAD in older people. One such
alternative is acceptance and commitment therapy (ACT),
an acceptance-based behaviour therapy [10] with a strong
evidence base in chronic pain [11], and a growing evidence
base in mental health conditions [12]. It aims to help people
(i) deal with uncomfortable thoughts, emotions and sensa-
tions; (ii) clarify what is important and meaningful to them
in their lives (i.e. their values); and (iii) identify ways to best
live their lives in accordance with their values, alongside their
uncomfortable experiences. With its focus on increasing
adaptive functioning and how best to live with uncomfort-
able thoughts, emotions and sensations (as opposed to chal-
lenging, changing or trying to eliminate them), ACTmay be
particularly appropriate for older people with TR-GADwho
have not derived benefit from interventions focused directly
on controlling such experiences [6]. Evidence that control-
orientated strategies (e.g. trying to eliminate problems that
cannot be solved) are detrimental to older people’s well-
being further supports this notion [13]. Another alternative
is interpersonal psychotherapy, which focuses on reducing
problematic mood by addressing interpersonal relationship
issues [14]. Although such issues may be particularly relevant
to older people, interpersonal psychotherapy may be less
applicable to those with TR-GAD as it is subject to the
arguments noted above.
To date, only one small study of ACT has been con-
ducted in older people with GAD [15]. This preliminary
RCT of ACT vs. CBT reported improvements in worry or
anxiety and depression with both interventions, but higher
treatment completion rates with ACT compared to CBT.
Although results were promising, this study was limited by
a small sample size (n = 16) and did not focus specifically on
those with TR-GAD. Therefore, it is not known whether an
approach that focuses on ‘living with’ rather than ‘getting rid
of’ uncomfortable experiences is acceptable to older people
with TR-GAD. Consequently, the aims of this study were
to examine the acceptability and feasibility of ACT for older
people with TR-GAD and to obtain preliminary estimates
of potential effectiveness.
Methods
All reporting is in accordance with the Consolidated Stan-






















































































Acceptance and commitment therapy for late-life TR-GAD
Description and Replication guidelines (checklists are pre-
sented in Appendices 1 and 2, available in Age and Ageing
online). Additional details about study methods are provided
in Appendix 3, available in Age and Ageing online. Ethical
approval was granted by the London-Camberwell St Giles
Research Ethics Committee (17/LO/1314).
Design
A pre-registered, uncontrolled, feasibility study (ISRCTN
Registry ISRCTN12268776). An uncontrolled study rather
than pilot RCT was conducted as specified by the commis-
sioning funder.
Participants
Participants were recruited from general practitioner (GP)
practices, primary and secondary care services within Lon-
don, UK, and the community. Eligible participants:
(1) Were aged ≥65 years with a primary diagnosis of GAD
as determined by the MINI International Neuropsychi-
atric Interview [16] and the Structured Clinical Inter-
view for diagnostic and statistical manual of mental
disorders (DSM)-IV Axis II Disorders [17];
(2) Had failed to respond to first-line treatment (i.e. still
experiencing moderate-to-severe GAD after 6 weeks of
an age-appropriate dose of antidepressant medication
or a course of individual psychotherapy [7]), failed to
tolerate this treatment, or previously refused it and
remained symptomatic;
(3) Were community living;
(4) Had capacity to provide informed consent for partici-
pation;
(5) Had sufficient English to understand study materials;
(6) Had not participated in previous qualitative interviews
[6];
(7) Had at least a 1 month interval between previous psy-
chotherapy and engagement in ACT.
Procedure
Potential participants were identified and approached about
the study through local clinicians and research databases, list
searches of GP electronic medical records and community
leaflets and advertisements. Service users were pre-screened
using the Generalised Anxiety Disorder-7 (GAD-7) [18],
and verbal consent for contact was sought from those scoring
≥11 on this scale (i.e. at least moderate GAD). Participants
who provided written informed consent and met eligibility
criteria were invited to participate.
Intervention
We used systematic, qualitative methods to develop and
optimise the relevance, acceptability and feasibility of a
manualised intervention for older people with TR-GAD [6].
The intervention comprised up to 16 one-to-one, face-to-
face sessions of ACT, with each session lasting up to 1 hour.
Sessions were delivered in person within the GP practice,
outpatient clinic or participant’s home, as soon as a therapist
became available. The first 14 sessions were weekly, while
the subsequent sessions were fortnightly in order to facilitate
ending of the intervention. Each session was associated with
a specific set of skills, metaphors, experiential exercises and
home practice tasks. All participants received usual care in
addition to ACT, comprising assessment, medication review
and management within primary or secondary care. Thera-
pists were qualified clinical psychologists, CBT therapists or
counselling psychologists, with a minimum of 1 year’s expe-
rience in delivering psychotherapy interventions. Therapists
were provided with weekly telephone group supervision and
consultation.
Treatment fidelity
All therapy sessions were recorded using encrypted digital
voice recorders. Ten percent of sessions were randomly
selected (stratified by therapist, phase of intervention and
phase of study recruitment) and assessed for treatment
fidelity by independent ACT therapists using an adapted
form of the ACT Treatment Integrity Coding Manual [19].
Data collection
A range of socio-demographic and clinical data were col-
lected face-to-face at screening and baseline. Data collec-
tion was conducted face-to-face or via telephone at 20-
week follow-up. Baseline assessments were completed in the
2 weeks prior to starting ACT.
Outcomes
The primary outcomes were
(i) Acceptability:
(a) Participants attending ≥60% sessions (i.e. ≥10 ses-
sions);
(b) ‘Satisfactory’ ratings of therapy on the satisfaction
with therapy subscale of the Satisfaction withTherapy
and Therapist Scale-Revised [20] at 20-week follow-
up. There is no set definition of what constitutes
‘satisfactory’ and so we defined this as a total score of
≥21/30.
(ii) Feasibility:
(a) Recruitment of ≥80% of the target sample size
(n = 40) in a 10-month recruitment period;
(b) Retention rate of ≥60% as measured by attendance at
the follow-up assessment.
Three out of four of these a priori indicators of success
needed to be met in order to demonstrate feasibility of the
study.
Secondary acceptability and feasibility outcomes are listed
in Table 1. Mental health outcomes were Geriatric Anxi-
ety Inventory (GAI) [21], Penn State Worry Questionnaire
(PSWQ) [22], Geriatric Depression Scale-15 (GDS-15) [23]
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Table 1. Secondary outcomes with respect to acceptability and feasibility
Secondary outcome measures Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acceptability
Failures to recruit due to lack of acceptability No reports of eligible participants not being recruited due to dissatisfaction with
the intervention being offered.
Participants dropped out due to lack of acceptability A low rate of loss to follow-up (n = 2) and a low rate of withdrawal from the
intervention alone (n = 2) due to dissatisfaction with the intervention.
CEQ after the first session of the interventiona Adequate mean ratings of credibility (16.5, SD 5.0) and expectancy (14.5, SD
5.0).
Adverse or serious adverse events A low rate of adverse or serious adverse events (n = 4 and n = 3, respectively), with
none deemed to be related to the intervention.
Feasibility
Eligible referrals The overall rate of conversion of referrals to eligible participants was 47%
(38/81).
Eligible participants recruited The majority of eligible participants came from community mental health teams
(n = 23, 61%), followed by Improving Access to Psychological Therapies services
(n = 9, 24%).
Failures to recruit due to feasibility issues There was only one case of an eligible participant not being recruited for
feasibility-related reasons.
Participants dropped out due to feasibility issues There was a relatively low rate of attrition due to feasibility-related reasons (n = 5,
14%).
CEQ=Credibility/Expectancy Questionnaire [43]. aCredibility and expectancy subscales ranged from 3 to 27, with higher scores indicating higher credibility/ex-
pectancy. Cost-related outcome measures were also collected but are reported elsewhere.
Statistical analyses
Categorical measures were summarised using frequencies
and percentages, while continuous measures were sum-
marised usingmeans and standard deviations or medians and
interquartile ranges for skewed distributions. Change scores
across time (with accompanying 95% confidence intervals)
were calculated for individuals who had observations at both
baseline and 20-week follow-up, and then averaged across
individuals. Change between baseline and 20-week follow-
up was estimated using a linear mixed model with a random
effect of participant to account for repeated measures from
the same individual. Reliable Change Index (RCI) and
Clinically Significant Change (CSC) scores were calculated
using the Leeds Reliable Change Indicator calculator [25] for
any mental health outcome that showed statistical evidence
of pre–post changes in linear mixed models.
Sample size
A sample size of 40 was chosen following conventional rec-
ommendations for feasibility studies [26] and an estimated
12.5% loss to follow-up based on a preliminary study of
ACT in older people with GAD [15].
Results
Study flow and baseline characteristics
Eighty-one potential participants were referred from 2 Jan-
uary 2018 to 31 October 2018, and 20-week follow-ups
were conducted between 8 June 2018 and 24 April 2019.
Thirty-seven eligible participants consented to participate in
the study: 7 (19%) were lost to follow-up (see Figure 1). Data
were collected from 92% (n = 34) of participants at baseline
and 81% (n = 30) of participants at 20-week follow-up.
Baseline characteristics are described in Table 2.
Session attendance
The mean waiting time for therapy was 10.2 weeks (SD
8.8). Twenty-two participants (59%) attended 16 sessions,
with 26 (70%) attending≥10 sessions.Themean number of
sessions completed by the 20-week follow-up was 12.1 (SD
3.6). Although only one participant (3%) had attended 16
sessions by this point, 24 participants (65%) had attended at
least 10 sessions. For ethical reasons, participants continued
receiving therapy beyond the 20-week follow-up, if they had
not received up to 16 sessions by this point. The number of
weeks taken to receive up to 16 sessions ranged from 6 to
35 weeks (excluding withdrawals from the intervention or
study).
Primary outcomes
The recruitment rate of 93% (37/40) and retention rate
of 81% (30/37) exceeded the set targets. Seventy percent
(26/37) of participants attended ≥60% sessions (i.e. ≥10
sessions). Sixty percent (18/30) of participants scored
≥21/30 on the satisfaction with therapy subscale, although
80% (24/30) were still undergoing the intervention at the
20-week follow-up.
Secondary outcomes
Table 1 displays the results of secondary acceptability and
feasibility outcomes. With respect to mental health out-
comes, there was a two-point reduction between baseline and
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Figure 1. Summary of recruitment and follow-up of participants in the study.
−3.83 to −0.76) and depression (GDS-15: −2.04; 95%
CI: −3.31 to −0.77) in the linear mixed model analysis
(see Table 3). There was also a three-point reduction in
psychological inflexibility (AAQ-II: −3.93; 95% CI: −7.16
to −0.70).
Data used to calculate RCI and CSC scores for the GAI,
GDS-15 and AAQ-II are outlined in Appendix 3, available
in Age and Ageing online. As shown in Table 4, 45% of
participants (13/29) showed a reliable improvement in scores
on the GAI at 20-week follow-up, with six (21%) of these
also meeting the criterion for clinically significant change
(i.e. scored below the clinical cut-off). For both the GDS-15
and the AAQ-II, 24% (7/29) showed a reliable improvement
in scores at 20-week follow-up, with five (17%) and four
(14%) of these, respectively, also meeting the criterion for
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Table 2. Demographic and clinical characteristics for all participants (n = 37)
Variable N (missing N , %) Mean (SD), median (IQR) or N (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age (years) 37 (0, 0%) 74.8 (6.3)
Sex 37 (0, 0%)
Female 30 (81%)
Male 7 (19%)
Ethnicity 37 (0, 0%)
Asian/Asian British 1 (3%)
Black/Black British 1 (3%)
Mixed 1 (3%)
White/White British 32 (86%)
Other 2 (5%)







Mean years of education 37 (0, 0%) 10.2 (2.9)
Highest educational qualification 37 (0, 0%)
Post-graduate university qualification (e.g. Masters) 1 (3%)
University qualification (e.g. Degree) 5 (14%)
College qualification (e.g. A level/Baccalaureate) 4 (11%)
High school qualification (e.g. O level/GCSE/GCE) 3 (8%)
High school leaving certificate 3 (8%)
No educational qualifications 15 (41%)
Unclear 6 (16%)
Employment status 37 (0, 0%)
Paid work 2 (5%)
Voluntary work 6 (16%)
Retired 28 (76%)
Other 1 (3%)
Mean GAD-7 total score (possible range 0–21)a 37 (0, 0%) 15.2 (2.7)
GAD-7 severity classification 37 (0, 0%)
Moderate (possible range 11–15) 22 (60%)
Severe (possible range 16–21) 15 (41%)







No. of participants meeting MINI diagnostic criteria 37 (0, 0%)
GAD 37 (100%)
Major depressive episode without melancholic features 8 (22%)
Major depressive episode with melancholic features 13 (35%)
Mood disorder with psychotic features 2 (5%)
Panic disorder 3 (8%)
Panic with agoraphobia 4 (11%)
Agoraphobia 7 (19%)




Psychotic disorders 0 (0%)
Manic episode 0 (0%)
Alcohol dependence 1 (3%)
Substance abuse 0 (0%)
No. of participants with ≥1 comorbid mental health disorder on the MINI 37 (0, 0%) 30 (81%)
Mean no. of mental health comorbidities on the MINI 37 (0, 0%) 1.5 (1.1)
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Table 2. Continued
Variable N (missing N , %) Mean (SD), median (IQR) or N (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unclear 3 (8%)
Current suicidal ideation without active intentb 37 (0, 0%)
Yes 27 (73%)
No 10 (27%)
History of suicide attempt or self-harm 37 (0, 0%)
Yes 11 (30%)
No 26 (70%)
No. of participants meeting screening criteria for DSM-V Axis II personality disorders 37 (0, 0%)
Avoidant 3 (8%)
Obsessive compulsive 3 (8%)
Borderline 2 (5%)
Dependent 1 (3%)
Current psychotropic medication 37 (0, 0%)
Yes 27 (73%)
No 10 (27%)
Mean no. of psychotropic medications at assessment 37 (0, 0%) 1.4 (1.2)
No. of participants with changes to psychotropic medication within 2 months of
assessment
37 (0, 0%) 5 (14%)
Previous pharmacotherapy 37 (0, 0%)
Yes 29 (78%)
No 8 (22%)
Median no. of different types or episodes of previous pharmacotherapy (tried or
declined)
37 (0, 0%) 1.0 (1.0–2.0)
Previous psychological therapy 37 (0, 0%)
Yes 31 (84%)
No 6 (16%)
Mean no. of different types or episodes of previous psychological therapy (tried or
declined)
37 (0, 0%) 1.7 (1.2)
Mean SMMSE total score (possible range 0–30)c 37 (0, 0%) 28.4 (1.5)
Cumulative Illness Rating Scale for Geriatrics 37 (0, 0%)
Mean total no. of endorsed categories (possible range 0–14)d 4.7 (2.1)
Mean total score (possible range 0–56)d 10.4 (5.0)
Mean Severity Indexe 2.1 (0.7)
Mean no. of level 3 severity categories (possible range 0–14)f 1.7 (1.3)
Mean no. of level 4 severity categories (possible range 0–14)g 0.2 (0.4)
MINI =Mini International Psychiatric Inventory. SMMSE= Standardised Mini-Mental State Examination [44]. aHigher scores indicate greater severity of GAD.
bPotential participants were not eligible to take part in the study if they were expressing suicidal ideation with active intent at screening. cHigher scores indicate
better global cognition. dHigher scores indicate poorer health in 14 categories (e.g. vascular, neurological and psychiatric illness). eSeverity Index =Total score/Total
no. of endorsed categories on the Cumulative Illness Rating Scale for Geriatrics [38]. fLevel 3 severity = severe, constant significant disability or ‘uncontrollable’
chronic problems. gLevel 4 severity = extremely severe, immediate treatment required, end organ failure or severe impairment in function.
reliable or clinically significant deterioration on the GAI,
GDS-15 and AAQ-II.
Treatment integrity
High rates of overall adherence to the manual (mean score
of 4.2/5, SD 0.8) and overall ACT competence of therapists
(mean score of 4.1/5, SD 0.8) were observed using the ACT
Treatment Integrity Coding Manual. Crucially, there was no
evidence of ACT-inconsistent items in the rated sessions nor
reports of ACT-inconsistent deviations from the manual.
Discussion
This study showed that it is feasible to recruit and retain
older people with TR-GAD in a study of ACT with a
20-week follow-up. Three out of four indicators of success
were met. Excellent feasibility in terms of recruitment and
retention, and good acceptability in terms of session atten-
dance were found, which was further supported by secondary
outcomes. However, the percentage of participants who were
satisfied with therapy was only adequate (60%). Finally,
although the study was not powered to examine clinical
effectiveness, there was preliminary evidence of improve-
ments in scores on the GAI, GDS-15 and AAQ-II from
baseline to 20-week follow-up. Furthermore, reliable changes
in scores were found in almost half (45%) of participants
on the GAI. This is promising, given that participants were
recruited on the basis of having a treatment-resistant dis-
order, and ACT, with its focus on ‘living better’ rather
than ‘feeling better’, is not primarily aimed at symptomatic
reduction.
Satisfaction with therapy may have been lower than
wished for numerous reasons. First, 80% of participants had
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Table 3. Estimated change in mental health outcome measures between baseline and 20-week follow-up
Baseline 20-week follow-up Analysis of changee Linear mixed modelf
Outcome
measure













































SD= standard deviation. GAI =Geriatric Anxiety Inventory. PSWQ=Penn State Worry Questionnaire. GDS-15 =Geriatric Depression Scale-15. AAQ-
II = Acceptance and ActionQuestionnaire-II. aHigher scores indicate greater anxiety. bHigher scores indicate greater worry. cHigher scores indicate greater depression.
dHigher scores indicate greater psychological inflexibility. eOnly includes participants with data at both timepoints. fIncludes participants with data at either
timepoint or both.
Table 4.Reliable change and clinically significant changes in participants with data at baseline and 20-week follow-up (n = 29)
Outcome measure Clinically significant
deterioration
Reliable deterioration No reliable change Reliable improvement Clinically significant
improvement
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Geriatric Anxiety
Inventory
0 (0%) 1 (3%) 15 (52%) 13 (45%) 6 (21%)
Geriatric Depression
Scale-15
0 (0%) 0 (0%) 22 (76%) 7 (24%) 5 (17%)
Action and Acceptance
Questionnaire-II
0 (0%) 3 (10%) 19 (66%) 7 (24%) 4 (14%)
Clinically significant improvement = improvement from pre-treatment that meets both Reliable Change Index (RCI) and Clinically Significant Change (CSC)
criteria (i.e. a reliable change that is also clinically significant). Reliable improvement = improvement from pre-treatment that meets RCI, but not CSC criteria
(i.e. a reliable change that is not clinically significant). No reliable change = the magnitude of any change following treatment is within the expected range due
to measurement error. Reliable deterioration = deterioration from pre-treatment that meets RCI, but not CSC criteria (i.e. a reliable change that is not clinically
significant). Clinically significant deterioration = deterioration from pre-treatment that meets both RCI and CSC criteria (i.e. a reliable change that is also clinically
significant). Established norms for clinical and non-clinical populations (means and standard deviations), estimates of reliability (Cronbach’s alpha) and cut-off
scores (indicating ‘recovery’) used to calculate reliable and clinically significant changes are listed in Appendix 3, available in Age and Ageing online.
follow-up. Satisfaction may have been higher if participants
had finished receiving therapy by this point. This suggests
that completing up to 16 sessions in 20 weeks was not
feasible, and that a longer time interval is necessary. Second,
there is no set definition of what constitutes ‘satisfactory’
on the satisfaction with therapy subscale and so this was
defined as a total score of ≥21/30. If a criterion of ≥18/30
had been chosen, which corresponds to a ‘neutral’ rating on
all items (i.e. the lowest limit of ‘satisfactory’), then 70% of
participants would have rated the therapy as ‘satisfactory’.
Third, qualitative feedback from participants and therapists
indicated that some participants struggled with the aim
of ACT to live as best a life as possible with worry and
anxiety, rather than trying to change or get rid of this.
Some participants reported they had been struggling with
worry for many years, and some continued to demonstrate
fusion with beliefs about their ability to change (e.g. due
to age), as well as strong attachment to self-narratives
(e.g. ‘I’ve always been a worrier’). This indicates that the
intervention may require further refinement, such as (i)
examining participants’ expectations about therapy and
motivation to change from the outset (e.g. the degree to
which they are wanting to get rid of anxiety); (ii) more
frequently revisiting the workability of control strategies and
beliefs about the self (e.g. looking at how well strategies for
getting rid of anxiety are helping the person to live their
life in service of their values); and (iii) including more
exercises and metaphors that facilitate acceptance rather
than avoidance of uncomfortable experiences and explicitly
linking this to values-driven behaviour. Other factors that
may influence satisfaction with therapy include treatment
credibility and treatment adherence. Both of these factors
were found to predict treatment satisfaction in an RCT of
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[27], and thus should be explored further in any larger-scale
study of ACT for TR-GAD.
Only a handful of studies have examined ACT in older
people. The majority have examined chronic pain [28–31],
with the remainder focusing on GAD [14], veterans with
depression [32], and those living in long-term care facili-
ties [33]. A preliminary RCT of ACT vs. CBT for older
people with GAD (n = 16) reported pre–post improvements
in worry and depressive symptoms, but not anxiety [14].
Improvements in depression were observed in an obser-
vational study of ACT for older veterans with depression
(n = 76) in a routine clinical setting [32]. Finally, a pilot
RCT of ACT vs. wait-list control for older people with
symptoms of depression and/or anxiety living in long-term
care facilities (n = 41) reported significantly lower depres-
sion but not anxiety scores following ACT [33]. Our find-
ings of pre–post improvements in depressive and anxiety
symptoms are consistent with these previous studies. Over-
all, these findings suggest that ACT may have the poten-
tial to reduce symptoms of anxiety and depression and
increase psychological flexibility in older people with TR-
GAD.
Two observations with respect to participant character-
istics merit further discussion. First, a bimodal distribution
of age of GAD onset was found, with 35% of partici-
pants (n = 13) experiencing difficulties for 1–5 years and
35% experiencing difficulties for over 30 years. This mirrors
other findings in working-age adults and older people with
GAD [34–36]. Whether there are differences in treatment
response between these sub-populations should be explored
further in a larger study given that higher rates of psy-
chiatric comorbidity have been reported in older people
with an earlier compared to later GAD onset [34], and
psychiatric comorbidity is associated with poorer treatment
response in GAD [37]. Second, psychiatric and medical
comorbidity was common, with 81% of participants (n = 30)
meeting criteria for one or more comorbid mental health
disorders, 73% (n = 27) reporting suicidal ideation with-
out active intent, and 78% (n = 29) reporting severe prob-
lems in at least one category on the Cumulative Illness
Rating Scale for Geriatrics [38]. While these rates may
seem high, they are unsurprising given that medical and
psychiatric comorbidities are associated with poor treat-
ment response in anxiety disorders [39] and strong asso-
ciations have been reported between GAD and suicidal
ideation, even after controlling for psychiatric comorbidity
[40–42].
To our knowledge, this is the first study to report the
acceptability, feasibility and preliminary estimates of the
effectiveness of a psychological intervention developed
specifically for older people with TR-GAD. However, there
are a few limitations of the study. First, the majority of
participants were White women in their 60s/70s, and so
the results cannot be generalised to a broader population.
Second, participants were only recruited from urban and
suburban areas within London, UK, further limiting external
validity. Third, as outcome measures were only assessed
at 0 and 20 weeks, it is uncertain whether any gains were
maintained or further gains made beyond 20 weeks. Finally,
as this was an uncontrolled feasibility study (and hence
any changes in outcomes could be due to non-specific
therapeutic factors such as social support or spontaneous
recovery), findings on mental health outcomes should be
interpreted with caution.
Conclusions
There was excellent evidence of feasibility and good evi-
dence of acceptability of ACT for older people with TR-
GAD. However, satisfaction with therapy scores suggested
that further refinement of the intervention may be neces-
sary. There was preliminary evidence of improvements in
anxiety, depression and psychological flexibility, with some
participants showing clinically meaningful change. Overall,
findings suggest that a fully powered RCT to evaluate the
clinical and cost-effectiveness of ACT for older people with
TR-GAD is warranted.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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